EGFR and pancreatic neoplasm: Nonetheless, controlled clinical trials on bevacizumab, a monoclonal antibody against VEGF and Cetuximab, a monoclonal antibody against epidermal growth factor receptor (EGFR), failed to demonstrate a survival benefit of anti-angiogenic therapy for patients with pancreatic cancer [15,16].